Perfect, thank you very much. That's very enlightening.
Last October, you published a report on the estimated costs of a single-payer universal drug plan. With such a plan, people will buy more drugs, since they're currently going without because prices are too high. We expect an increase in drug purchases of just over 13%.
Despite this, you say that the savings we could collectively achieve on drug prices would be on the order of $1.4 billion in 2024-25 and could reach $2.2 billion in 2027-28. How do you reconcile these two phenomena?